Overview

Cephalogics is developing a noninvasive portable imaging system to provide clinicians with valuable measures of cerebral perfusion status in brain injured patients.  Undetected perfusion deficits lead to ischemia and severe adverse outcomes.  The Cephalogics system detects perfusion deficits and alerts the clinician so they can intervene early to avoid ischemia.  Primary and secondary markets of interest are Neurocritical care units and Emergency Departments.  The Cephalogics system would be used to identify perfusion deficits and facilitate early intervention to avoid the adverse outcomes associated with ischemia. 

Cephalogics’ technology is the result of a partnership between Allied Minds and Dr. Joseph P. Culver at Washington University in St. Louis. Dr. Culver is an Assistant Professor in the Department of Radiology and a diffuse optical tomography expert.

Technology

The Cephalogics system utilizes Diffuse Optical Tomography (DOT) technology to provide non-invasive, bedside imaging of multiple cerebral vascular regions.  Each sensor consists of innovative, compact, high-density arrays using NIR light sources and detectors to provide hundreds of simultaneous spatial measurements. These measurements are processed in real time by proprietary algorithms to produce spatial maps of cerebral tissue oxygen saturation and other perfusion measures.   This allows clinicians to “see” the brain through hair, skin and skull.   The compact, convenient and portable design makes the Cephalogics system easy to use in a variety of care settings.  Animal and human testing has yielded impressive results and demonstrated the performance of the technology. 

Future Goals

Initial commercialization efforts will focus on brain-injured patients.  Primary and secondary markets include Neurocritical care and Emergency Departments where the device would be used to identify perfusion deficits and enable early interventions to avoid ischemia in the millions of patients with injured brains.  Additional markets of interest include ambulance and cardiac surgery.









Announcements

See All
01-Jun-2011

Cephalogics hires Russ Herrig as head of Research and Development.

Boston, MA - Cephalogics is pleased to announce that Russ Herrig has joined its team as head of Research & Development. Russ is a medical device engineering executive with..

21-Dec-2010

Cephalogics Receives Discovery Project Grant

Boston, Massachusetts -- Cephalogics, LLC was awarded a $161,144 grant from the Qualifying Therapeutic Discovery Project program, which is provided under the new section 48D o..

Please visit Cephalogics at

Contact Cephalogics

  • • Required
  • Captcha Image
  • Phone Email

Privacy Policy Terms of Use